SLCTR_2012_004Completed
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
A 24-week, Randomized, Double-blind, Active-controlled, Parallel Group Trial to Assess the Superiority of Oral Linagliptin and Metformin Compared to Linagliptin Monotherapy in Newly Diagnosed, Treatment-naïve, Uncontrolled Type 2 Diabetes Mellitus Patient
Boehringer Ingelheim India (Pvt) LtdPhase 3Sri Lanka Clinical Trials Registry
VerifiedSri Lanka Clinical Trials Registry
Study focus
- Disease/Condition
- Diabetes Mellitus, Type 2
- Study type
- Interventional
Sponsor & location
- Primary sponsor
- Boehringer Ingelheim India (Pvt) Ltd
- Location
- Canada, Estonia, Guatemala, India, Israel, Malaysia, Mexico, Philippines, Poland, Russia, Slovakia,
Timeline & enrollment
- Phase
- Phase 3
- Start date
- May 23, 2012
- End date
- N/A
ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with multiple complications
Data source
- Registry
- Sri Lanka Clinical Trials Registry
- Trial ID
- SLCTR_2012_004
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for SLCTR_2012_004 through Pure Global AI's free database. This Phase 3 trial is sponsored by Boehringer Ingelheim India (Pvt) Ltd and is currently Completed. The study focuses on Diabetes Mellitus, Type 2.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Sri Lanka Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.